11 results on '"Vandewalker ML"'
Search Results
2. An Update on Treatment Options for Children and Adults With Asthma.
- Author
-
Kaplan AG and Vandewalker ML
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Adult, Asthma prevention & control, Child, Child Health Services organization & administration, Health Education standards, Humans, Severity of Illness Index, United States, Asthma therapy, Disease Management, Patient Education as Topic standards, Quality of Health Care
- Published
- 2018
3. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy.
- Author
-
Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, Kaiser HB, Vandewalker ML, Bernstein J, Toler WT, Prillaman BA, Dalal AA, Lee LA, and Philpot EE
- Subjects
- Administration, Intranasal, Administration, Oral, Adult, Androstadienes adverse effects, Double-Blind Method, Female, Histamine Antagonists adverse effects, Humans, Male, Middle Aged, Nasal Obstruction drug therapy, Quality of Life, Rhinitis, Allergic, Seasonal complications, Rhinitis, Allergic, Seasonal physiopathology, Rhinitis, Allergic, Seasonal psychology, Sleep Wake Disorders etiology, Terfenadine administration & dosage, Terfenadine adverse effects, Treatment Outcome, Androstadienes administration & dosage, Histamine Antagonists administration & dosage, Rhinitis, Allergic, Seasonal drug therapy, Sleep Wake Disorders drug therapy, Terfenadine analogs & derivatives
- Abstract
Nasal symptoms of allergic rhinitis are an important cause of sleep disturbance. Reduction of nasal symptoms, particularly nasal obstruction, has been linked to improvements in self-reported sleep quality. The enhanced-affinity intranasal corticosteroid fluticasone furoate and the oral antihistamine fexofenadine were compared with respect to nighttime symptoms of seasonal allergic rhinitis. In two randomized, double-blind, double-dummy, parallel-group studies, patients received fluticasone furoate nasal spray (FFNS),110 microg (study 1, n = 312; study 2, n = 224); fexofenadine, 180 mg (study 1, n = 311; study 2, n = 227); or placebo (study 1, n = 313; study 2, n = 229) once daily for 2 weeks. Fluticasone furoate was more effective (p < 0.001) than fexofenadine and placebo in both studies with respect to the mean changes from baseline over the treatment period in the nighttime symptoms score, nighttime reflective total nasal symptom score, predose instantaneous nasal symptom score, and morning peak nasal inspiratory flow. Fluticasone furoate was more effective than placebo (p
- Published
- 2009
- Full Text
- View/download PDF
4. Facial angioedema in children due to ladybug (Harmonia axyridis) contact: 2 case reports.
- Author
-
Davis RS, Vandewalker ML, Hutcheson PS, and Slavin RG
- Subjects
- Angioedema diagnosis, Angioedema therapy, Animals, Child, Preschool, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact therapy, Emergency Medical Services, Facial Dermatoses diagnosis, Facial Dermatoses therapy, Humans, Male, Angioedema immunology, Coleoptera, Dermatitis, Allergic Contact immunology, Facial Dermatoses immunology
- Abstract
Background: Only 9 adult cases of immediate-hypersensitivity reaction to ladybugs, also known as Asian lady beetles (Harmonia axyridis), have been documented in the literature. These patients have all shown symptoms of allergic rhinoconjunctivitis or asthma from exposure to ladybugs., Objective: To describe the first pediatric patients with severe allergic facial angioedema requiring emergency department management after exposure to ladybugs., Methods: Evidence of IgE-mediated hypersensitivity to ladybugs was documented by positive skin prick test reactions, correlating with exposure history., Results: Two cases in preschool boys had similar features, although they were evaluated and tested by 2 different allergists. Both patients developed severe facial or periocular angioedema with no significant respiratory involvement after exposure to ladybugs outside their infested homes. Both patients required an emergency department visit for treatment. Allergy evaluation using ladybug extract for skin prick testing showed markedly positive reactions in both patients. There were no further episodes after environmental control measures were instituted., Conclusions: Although allergic respiratory or cutaneous reactions to ladybugs are uncommon, a high index of suspicion from exposure history and confirmatory skin testing can be conclusive for the diagnosis.
- Published
- 2006
- Full Text
- View/download PDF
5. The diagnosis and management of sinusitis: a practice parameter update.
- Author
-
Slavin RG, Spector SL, Bernstein IL, Kaliner MA, Kennedy DW, Virant FS, Wald ER, Khan DA, Blessing-Moore J, Lang DM, Nicklas RA, Oppenheimer JJ, Portnoy JM, Schuller DE, Tilles SA, Borish L, Nathan RA, Smart BA, and Vandewalker ML
- Subjects
- Adult, Algorithms, Child, Humans, Sinusitis diagnosis, Sinusitis therapy
- Published
- 2005
- Full Text
- View/download PDF
6. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray.
- Author
-
Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vandewalker ML, Wanderer A, Damaraju CV, Nolop KB, and Mesarina-Wicki B
- Subjects
- Administration, Intranasal, Anti-Inflammatory Agents adverse effects, Child, Double-Blind Method, Female, Glucocorticoids, Growth Disorders chemically induced, Humans, Male, Mometasone Furoate, Pregnadienediols adverse effects, Anti-Inflammatory Agents therapeutic use, Growth drug effects, Pregnadienediols therapeutic use, Rhinitis, Allergic, Perennial drug therapy
- Abstract
Objective: Intranasal corticosteroids are used widely for the treatment of allergic rhinitis because they are effective and well tolerated. However, their potential to suppress growth of pediatric subjects with allergic rhinitis continues to be a concern, particularly in light of reports of growth suppression after treatment with intranasal beclomethasone dipropionate or intranasal budesonide (see the article by Skoner et al in this month's issue). A 1-year study of prepubertal patients between 3 and 9 years of age with perennial allergic rhinitis was conducted to assess the effects on growth of mometasone furoate aqueous nasal spray (MFNS), a new once-daily (QD) intranasal corticosteroid with negligible bioavailability., Methods: This was a randomized, placebo-controlled, double-blind, multicenter study. Ninety-eight subjects were randomized to treatment with either MFNS 100 microg QD or placebo for 1 year. Each subject's height was required to be between the 5th and 95th percentile at baseline, and skeletal age at screening was required to be within 2 years of chronological age, as determined by left wrist x-rays. Washout periods for medications that affect either childhood growth or allergic rhinitis symptoms were established based on estimated period of effect, and these medications were prohibited during the study. However, short courses of either oral prednisone lasting no longer than 7 days or low-potency topical dermatologic corticosteroids lasting no longer than 10 days were permitted if necessary. Height was measured with a calibrated stadiometer at baseline and at 4, 8, 12, 26, 39, and 52 weeks, and the primary safety variable was the change in standing height. The rate of growth was also calculated for each subject as the slope (linear regression) of the change in height from baseline using data from all visits of subjects who had at least 2 visits. Hypothalamic-pituitary-adrenocortical- (HPA)-axis function was assessed via cosyntropin stimulation testing at baseline and at 26 and 52 weeks. All analyses were based on all randomized subjects (intent-to-treat principle). The change from baseline in standing height was analyzed by a 2-way analysis of variance that extracted sources of variation attributable to treatment, center, and treatment-by-center interaction., Results: Demographic characteristics were similar at baseline. Eighty-two subjects completed the study (42 in the MFNS group and 40 in the placebo group), and 93% of subjects achieved at least 80% compliance with therapy. After 1 year of treatment, no suppression of growth was seen in subjects treated with MFNS, and mean standing heights were similar for both treatment groups at all time points. For the primary safety variable (change in height from baseline), both treatment groups were similar at all time points except for weeks 8 and 52. Subjects treated with MFNS had a slightly greater mean increase in height than subjects treated with placebo at these time points: the change in height was 6.95 cm versus 6.35 cm at the 1-year time point. However, the rate of growth (.018 cm/day) averaged for all time points over the course of the study was similar for both treatment groups. Additional analyses found that MFNS did not retard growth in any sex or age subgroup of subjects. The use of exogenous corticosteroids other than the study drug was also similar among the 2 treatment groups. Results from cosyntropin stimulation testing confirmed the absence of systemic effects of MFNS. The change from baseline in the difference between prestimulation and poststimulation levels was similar for both treatment groups after 1 year of treatment, with no evidence of HPA-axis suppression in MFNS-treated subjects at any time point. Incidences of treatment-related adverse events were similar for both treatment groups, with 16% of MFNS-treated subjects reporting adverse events, compared with 22% of placebo-treated subjects., Conclusions: (ABSTRACT TRUNCATED)
- Published
- 2000
- Full Text
- View/download PDF
7. Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group.
- Author
-
Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalker ML, and Konig P
- Subjects
- Administration, Inhalation, Androstadienes adverse effects, Anti-Asthmatic Agents adverse effects, Anti-Asthmatic Agents pharmacology, Asthma physiopathology, Child, Child, Preschool, Dose-Response Relationship, Drug, Double-Blind Method, Female, Fluticasone, Glucocorticoids adverse effects, Glucocorticoids pharmacology, Humans, Male, Androstadienes administration & dosage, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy, Glucocorticoids therapeutic use, Growth drug effects
- Abstract
Objective: To determine whether inhaled fluticasone propionate has long-term effects on growth in children with persistent asthma., Study Design: In a double-blind, randomized, parallel-group, multicenter study, 325 prepubescent children with persistent asthma and normal growth rates were treated with placebo or inhaled fluticasone propionate powder 50 microg or 100 microg administered twice daily by a breath-actuated device for 1 year. Growth was evaluated monthly, whereas other safety variables and pulmonary function were evaluated periodically., Results: The prepubescent patients showed no statistically significant differences in mean height, mean growth velocity, or mean skeletal age between any of the treatment groups at any time. Over a period of 1 year, mean height (+/- SE) increased 6.15 +/- 0.17 cm in the placebo group, 5.94 +/- 0.16 cm in the fluticasone propionate 50 microg group, and 5.73 +/- 0.13 cm in the fluticasone propionate 100 microg group (p = 0.308, overall)., Conclusions: Prepubescent children treated with fluticasone propionate 50 microg and 100 microg administered twice daily for 1 year grew at rates similar to placebo-treated control subjects and at rates equal to expected growth velocity for age.
- Published
- 1998
- Full Text
- View/download PDF
8. Allergen immunotherapy.
- Author
-
Vandewalker ML
- Subjects
- Allergens immunology, Humans, Asthma therapy, Immunotherapy
- Published
- 1997
9. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray.
- Author
-
Graft D, Aaronson D, Chervinsky P, Kaiser H, Melamed J, Pedinoff A, Rosen JP, Schenkel EJ, Vandewalker ML, Keim A, Jensen PK, Nolop K, and Mesarina-Wicki B
- Subjects
- Administration, Intranasal, Beclomethasone administration & dosage, Beclomethasone adverse effects, Double-Blind Method, Glucocorticoids, Humans, Immunosuppressive Agents administration & dosage, Mometasone Furoate, Pregnadienediols adverse effects, Anti-Inflammatory Agents administration & dosage, Pregnadienediols administration & dosage, Rhinitis, Allergic, Seasonal prevention & control
- Abstract
Background: Topical nasal corticosteroids have become a mainstay of treatment for the symptoms of seasonal allergic rhinitis (SAR). It is likely that topical corticosteroids, by blocking an initial influx of inflammatory cells in the nasal mucosa induced by aeroallergens, may have a preventive effect on nasal allergy symptoms when administered before the pollen season., Objective: This study was designed to assess the efficacy and safety of an 8-week course of mometasone furoate nasal spray (MFNS), 200 micrograms once daily, in the treatment of SAR compared with beclomethasone dipropionate aqueous nasal spray (BDP), 168 micrograms twice daily, and placebo vehicle, when treatment is initiated before the anticipated onset of the ragweed season., Methods: Three hundred forty-nine patients with SAR to ragweed pollen from nine centers in the Northeast and Midwest of the United States were randomized to one of the three intranasal study medications (MFNS, 200 micrograms once daily, BDP, 168 micrograms twice daily, or placebo vehicle), starting 4 weeks before the estimated start of the ragweed season., Results: The proportion of "minimal symptom" days (total nasal symptom score < or = 2) was statistically significantly higher in both the MFNS and BDP groups when compared with the placebo vehicle group (p < 0.01). The two active treatment groups were not statistically significantly different from each other. MFNS and BDP displayed a similar safety profile that did not differ from placebo., Conclusions: This suggests that MFNS, 200 micrograms (once daily), is a useful therapy in the prophylactic treatment of SAR.
- Published
- 1996
- Full Text
- View/download PDF
10. Hypereosinophilia, neurologic, and gastrointestinal symptoms after bee-pollen ingestion.
- Author
-
Lin FL, Vaughan TR, Vandewalker ML, and Weber RW
- Subjects
- Adult, Animals, Bees, Diarrhea etiology, Female, Humans, Nausea etiology, Eosinophilia etiology, Food Hypersensitivity etiology, Gastrointestinal Diseases etiology, Nervous System Diseases etiology, Pollen
- Abstract
A patient developed hypereosinophilia (13,440 cells per cubic millimeter) 6 weeks after beginning the ingestion of bee pollen. Symptoms included generalized malaise, headache, nausea, abdominal pain diarrhea, generalized pruritus, and decreased memory. Evaluation revealed no other known cause for the patient's hypereosinophilia, which resolved after bee-pollen ingestion was stopped. The product contained a mixture of entomophilous and anemophilous pollens to which the patient was skin test positive. An open challenge with the bee pollen later reproduced the presenting symptoms with a concomitant rise of the eosinophil count from 207 to 890 cells per cubic millimeter. The patient has since remained well avoiding bee pollen. This study strongly suggests that hypereosinophilia with attendant pathophysiologic disturbances may be an adverse reaction to bee-pollen ingestion in atopic individuals.
- Published
- 1989
- Full Text
- View/download PDF
11. Addition of terbutaline to optimal theophylline therapy. Double blind crossover study in asthmatic patients.
- Author
-
Vandewalker ML, Kray KT, Weber RW, and Nelson HS
- Subjects
- Administration, Intranasal, Administration, Oral, Adolescent, Adult, Aged, Asthma physiopathology, Child, Clinical Trials as Topic, Double-Blind Method, Drug Therapy, Combination, Electrocardiography, Female, Humans, Male, Middle Aged, Monitoring, Physiologic, Pulmonary Ventilation, Random Allocation, Terbutaline administration & dosage, Terbutaline toxicity, Theophylline administration & dosage, Asthma drug therapy, Terbutaline therapeutic use, Theophylline therapeutic use
- Abstract
The efficacy and side effects of oral or inhaled terbutaline were examined in 13 mild-to-moderate asthmatic patients (ages 12 to 71 years) on maintenance theophylline (levels 10 to 25 micrograms/ml). In a crossover design, each patient received for two weeks oral terbutaline, 5 mg qid, inhaled terbutaline, 400 micrograms qid, or identical placebo tablets or metered-dose inhalers. Prior to each double-blind period, terbutaline was given for two weeks to ensure development of beta-adrenergic subsensitivity. Home-monitored peak flows and need for supplementary bronchodilators were significantly improved with both oral and inhaled terbutaline, but only the inhaled drug significantly decreased symptoms. Long-term terbutaline, either oral or inhaled, added to maintenance theophylline improved the patients' pulmonary function. The inhaled drug also improved the patients' clinical status as reflected by asthma symptom scores and need for extra bronchodilator. Combining terbutaline with theophylline did not produce evidence of cardiotoxicity.
- Published
- 1986
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.